HFS
KRYS icon

Hantz Financial Services’s Krystal Biotech KRYS Stock Holding History

Hantz Financial Services’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173K Sell
465
-9
-2% -$2.69K ﹤0.01% 1167
2026
Q1 		$122K Buy
474
+103
+28% +$27.4K ﹤0.01% 1209
2025
Q4 		$91K Buy
371
+79
+27% +$16.6K ﹤0.01% 1179
2025
Q3 		$52K Buy
292
+111
+61% +$16.6K ﹤0.01% 1215
2025
Q2 		$25K Buy
181
+179
+8,950% +$26.3K ﹤0.01% 1184
2025
Q1 		$0 Buy
+2
New +$336 ﹤0.01% 1852

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Hantz Financial Services's KRYS Position: Q2 2026 in Review

Hantz Financial Services reduced its Krystal Biotech (KRYS) stake by 1.9% in Q2 2026, selling an estimated $2.69K and leaving 465 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #1167.

Hantz Financial Services first reported a position in KRYS in Q1 2025 and has held it in 6 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Hantz Financial Services held 465 shares of Krystal Biotech worth $173K as of Q2 2026.
  • Hantz Financial Services sold 9 Krystal Biotech shares in Q2 2026, an estimated $2.69K.
  • Krystal Biotech made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #1167 holding.
  • Hantz Financial Services first reported a position in Krystal Biotech in Q1 2025 and has held it in 6 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.